The addition of Bacillus Calmette-Guérin to ERBT significantly reduced 1-year recurrence rates among patients with high-risk, muscle-invasive disease.
Jeremy Teoh, MBBS, FRCSEd, FCSHK, FHKAM
Advertisement
Articles by Jeremy Teoh, MBBS, FRCSEd, FCSHK, FHKAM
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
2
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
3
Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer
4
Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers
5